Search
Poliovirus type 1 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10795ApprovedInvestigationaltype 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by
Poliovirus type 3 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10797ApprovedInvestigationaltype 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by
UB-612
go.drugbank.com/drugs/DB16444InvestigationalThe UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653]. … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalAdecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
Virginiamycin M1
go.drugbank.com/drugs/DB01669ExperimentalIt is produced by Streptomyces graminofaciens and other bacteria.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Lumicitabine
go.drugbank.com/drugs/DB14808InvestigationalTablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations). … Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and
MK-4721
go.drugbank.com/drugs/DB05933InvestigationalMK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients
Carbocromen
go.drugbank.com/drugs/DB13279ApprovedWithdrawnCarbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].